Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilotinib vs Imatinib in Ph+ CML-CP with Suboptimal Response
NCT00519090Phase 3Terminated
- Sponsor
- Novartis
- Start
- Oct 2007
- Primary completion
- Oct 2008
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 3, randomised, open-label trial of nilotinib in chronic myeloid leukemia (CML) (2 arms), sponsored by Novartis. Primary endpoint: Complete Cytogenetic Response Rate at 12 months. Started Oct 2007; status: terminated.
02
Drugs
nilotinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT00519090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00519090.